Clinical trial
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
NCT00027976 · University of Alabama at Birmingham, Other · Withdrawn
Key facts
| NCT number | NCT00027976 |
|---|---|
| Title | Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses |
| Official title | A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Precancerous Condition |
| Intervention type | Drug |
| Interventions | celecoxib, Placebo |
| Enrollment | 0 |
| Start date | Dec 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: